REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trialJavier Martín‐Broto, Virginia Martínez-Marín, Javier Martínez‐Trufero et al.|Molecular Cancer|2023Cited by 27
Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.Ulrich Keilholz, Jérôme Fayette, Andrzej Kawecki et al.|Journal of Clinical Oncology|2018Cited by 5